Why this study matters
Usher syndrome is a genetic condition in which hearing loss occurs alongside progressive vision impairment. For affected individuals and families, identifying the precise genetic cause can replace uncertainty with an explanation, help guide clinical care, and inform family planning discussions. A 2026 study in Genetic Testing and Molecular Biomarkers reports disease-associated changes in MYO7A in two consanguineous families from Balochistan, Pakistan who had both hearing loss and vision impairment.
The findings are particularly important because changes affecting both copies of the MYO7A gene are an established cause of Usher syndrome type 1 (USH1). This form of Usher syndrome is characterized by congenital or early deafness, progressive loss of vision, and vestibular areflexia—a marked reduction or absence of normal balance-system reflexes. By providing a molecular diagnosis in these families, the research expands knowledge of the genetic changes associated with USH1 and illustrates the value of genetic testing for syndromic hearing loss.
The genetic context: why consanguinity matters
Hearing loss has many possible causes and can vary substantially from one person to another. The World Health Organization estimates that about 1.5 billion people worldwide live with some degree of hearing loss, with this number projected to reach 2.5 billion by 2050. A substantial portion of congenital and early-onset hearing loss has a genetic basis.
The families in this study were consanguineous, meaning the parents were biologically related. Consanguinity can increase the likelihood that both parents carry the same recessive gene variant inherited through a shared ancestor. If a child inherits the altered gene copy from each parent, they may develop an autosomal recessive condition.
This pattern is especially relevant for Usher syndrome type 1 caused by MYO7A. The affected person typically has variants in both copies of the gene, often described as biallelic variants. Studying families in communities where consanguineous marriage is more common can therefore be particularly informative for finding genetic causes of inherited hearing and vision disorders.
Two MYO7A variants identified
The researchers investigated two families, designated HL-76 and HL-79, from Balochistan, Pakistan. Both families included people with hearing loss and vision impairment. The team used exome sequencing, a method that examines the protein-coding regions of genes, followed by Sanger sequencing to verify the findings and assess whether the variants tracked with the condition within each family.
In family HL-79, the researchers identified the MYO7A variant c.487G>A, which changes the amino acid glycine to arginine at position 163 of the protein: p.(Gly163Arg). This is a recurrent variant, meaning it has been reported before. It has previously been classified in ClinVar and published reports as pathogenic or likely pathogenic.
In family HL-76, the team found c.4079A>G, changing aspartic acid to glycine at position 1360: p.(Asp1360Gly). This variant may represent a novel addition to the known spectrum of disease-associated MYO7A changes. Computer-based prediction tools indicated that both identified variants were likely damaging to the protein.
Importantly, the variants cosegregated with the condition in their respective families. In accessible terms, this means the genetic findings followed the expected inheritance pattern among affected and unaffected relatives, strengthening the evidence that they explain the families’ syndromic hearing loss and vision impairment.
From a genetic result to clinical care
A molecular diagnosis can have meaningful practical consequences. When hearing loss and vision impairment occur together, recognizing an underlying Usher syndrome diagnosis can support coordinated care across hearing, eye, and balance needs. It can also help families anticipate the progressive vision component associated with USH1 and plan for changing accessibility needs over time.
For relatives, identifying the responsible gene and variant enables more informed genetic counseling. Family members may be able to learn whether they carry a relevant MYO7A variant, while couples can discuss recurrence risks in the context of autosomal recessive inheritance. At a population level, findings such as these contribute evidence that can improve the interpretation of genetic test results in families with similar ancestry and clinical features.
Implications for future treatments and research
This study does not evaluate a treatment, but it provides a key building block for future therapeutic research: a confirmed genetic diagnosis. Treatments designed around a specific gene require confidence about which gene is involved and which disease-causing variants are present. Expanding the catalog of MYO7A variants can therefore help researchers better define potential patient populations for future gene-targeted research.
The potentially novel p.(Asp1360Gly) finding is especially valuable in this respect. As additional families are studied, researchers can gather more evidence about how individual MYO7A variants affect the protein and influence clinical features. This can refine variant classification and deepen understanding of the biological pathways involved in Usher syndrome.
Looking ahead
The report from these two Pakistani families underscores a wider message: genetic testing can be central to understanding syndromic hearing loss. By linking clinical features to specific MYO7A variants, the study offers these families a molecular explanation while adding to the global picture of Usher syndrome type 1. Continued research across diverse populations will be essential for improving genetic diagnosis, counseling, clinical management, and the foundations for future gene-focused approaches.

